SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Q2 2023 vs. Q1 2023
How the institutions holding SAB Biotherapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 14 | 10 | −4 |
| Shares | 1.74M | 846.5K | −889.5K (−51.2%) |
| Value | $51.6K | $88.4K | +$36.7K (+71.1%) |
New holders (2)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 100 | $10 | 0.00% |
| Clear Street LLC | 100 | $10 | 0.00% |
Sold out (6)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Shaolin Capital Management LLC | 498,109 | $18.0K |
| Balyasny Asset Management LLC | 281,107 | $15.8K |
| Equitec Proprietary Markets, LLC | 45,000 | $1.62K |
| Meteora Capital, LLC | 35,446 | $1.28K |
| Flow Traders U.S. LLC | 15,938 | $1.00K |
| Jane Street Group, LLC | 10,628 | $600 |